Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo equivalent Clear all

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 7
States / cities: Birmingham, Alabama • Concord, California • Fresno, California + 4 more

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • San Antonio, Texas

Conditions: Induction of Labor Affected Fetus / Newborn
Interventions: Propranolol, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Lung Disease, Bronchopulmonary Dysplasia
Interventions: Spironolactone, Placebo; Drug
Lead sponsor: West Virginia University Healthcare; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Moderate or Severe Hypoxic-ischemic Encephalopathy in Newborns
Interventions: Infusion of autologous cord blood, Placebo; Biological
Lead sponsor: Michael Cotten; Other
Eligibility: 0 Hours to 6 Hours
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Acute Respiratory Distress Syndrome, Infections
Interventions: Rhu-pGSN, normal saline; Drug
Lead sponsor: BioAegis Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 11
States / cities: Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 7 more

Conditions: Osteoarthritis of the Knee
Interventions: HLXL; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 40 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Frailty
Interventions: Ghrelin Infusion - Healthy, Ghrelin Infusion - Frail, Placebo Infusion -Healthy, Placebo Infusion - Frail; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 70 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Fibromyalgia
Interventions: Ketotifen, Placebo (Sugar Pill); Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Atherosclerosis
Interventions: 25 gm soy protein supplement, Placebo; Dietary Supplement · Other
Lead sponsor: University of Southern California; Other
Eligibility: 30 Years and older · Female only
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy, Parkinson Disease
Interventions: Lu AF82422, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: Glendale, California • Hollywood, Florida • Orlando, Florida + 1 more

Conditions: Vitamin A Status
Interventions: b-carotene, retinyl palmitate, placebo; Dietary Supplement
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Davis, California

Conditions: Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions: palbociclib, Cetuximab, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 14
States / cities: La Jolla, California • San Diego, California • Louisville, Kentucky + 7 more

Conditions: Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis
Interventions: Mepolizumab, Prednisolone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 14
States / cities: Denver, Colorado • Bethesda, Maryland • Boston, Massachusetts + 10 more

Conditions: The Frailty Syndrome
Interventions: Ghrelin Group 1, Ghrelin Group 2; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 70 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dravet Syndrome
Interventions: ZX008 (Fenfluramine Hydrochloride), Matching Placebo; Drug
Lead sponsor: Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: San Francisco, California • Aurora, Colorado • Chicago, Illinois + 2 more

Conditions: Alzheimer's Disease, Huntington's Disease
Interventions: Dimebon IR, Dimebon Transdermal; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Prediabetes, Type 2 Diabetes
Interventions: Metformin, Liraglutide, Glargine, Placebo; Drug
Lead sponsor: RISE Study Group; Network
Eligibility: 20 Years to 65 Years
Enrollment: 267 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 4
States / cities: Chicago, Illinois • Indianapolis, Indiana • Seattle, Washington

Conditions: Sickle Cell Disease
Interventions: Crovalimab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Detroit, Michigan • Madison, Mississippi • New York, New York + 1 more

Conditions: Obesity, Weight Loss
Interventions: Empagliflozin Arm, Control Arm, Exercise capacity VO2 maximum determination, Exercise Challenge; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pitt Hopkins Syndrome
Interventions: MTP-101P, Vancomycin, Magnesium Citrate, Antacid, Placebo MTP-101P, Placebo Vancomycin; Combination Product
Lead sponsor: Gut-Brain-Axis Therapeutics Inc.; Other
Eligibility: 5 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Depression, Postpartum, Anxiety Disorders, Stress, Psychological
Interventions: Intranasal Oxytocin, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Female only
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Systemic Lupus Erythematosus
Interventions: Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose, Placebo; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 14
States / cities: Torrance, California • Brandon, Florida • Miami, Florida + 10 more

Conditions: Autism Spectrum Disorders
Interventions: Syntocinon (synthetic oxytocin), Placebo; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 12 Years to 17 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin

Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes

Propranolol Versus Placebo for Induction of Labor in Nulliparous Patients

Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease

A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy

Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

Dose Escalation Study Of Chinese Herbs In Osteoarthritis Of The Knee

Ghrelin in Healthy and Frail Older Women

Novel Use of (Oral) Ketotifen for the Treatment of Fibromyalgia: A Pilot Study

Women's Isoflavone Soy Health (WISH) Trial

Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease

Effect of Small Daily Doses of B-carotene on Breast Milk Retinol

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921

Ghrelin Dose Finding In Frail Elderly

A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome

A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin

RISE Adult Medication Study

A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors

Microbiota Transfer Therapy for Children and Adults With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders

Inhaled Oxytocin and HPA Axis Reactivity

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

Intranasal Oxytocin and Learning in Autism